FORA:NASDAQForian Inc. Analysis
Data as of 2026-04-04 - not real-time
$2.10
Latest Price
6/10Risk
Risk Level: Medium
Executive Summary
Forian Inc. trades at $2.10, essentially flat against its 20‑day SMA (2.06) and just below its 200‑day SMA (2.10), but the stock sits at a key resistance level of $2.10 and a support of $2.01. Technicals show a neutral‑to‑slightly‑overbought RSI (58) and a modest bullish MACD histogram, while the broader market is in an "Extreme Greed" phase (fear‑greed index 78.8).
Fundamentally, the company posted a 37% revenue surge to $30.3 M and maintains a solid 53% gross margin, yet it remains loss‑making with a –24% operating margin and negative EPS. Cash balances are strong ($31.5 M) against negligible debt, and free cash flow is positive. The discounted cash‑flow model values the firm at $5.64, implying a substantial undervaluation relative to the current price, while the forward PE (23.3×) sits just below the industry average (25.7×).
Fundamentally, the company posted a 37% revenue surge to $30.3 M and maintains a solid 53% gross margin, yet it remains loss‑making with a –24% operating margin and negative EPS. Cash balances are strong ($31.5 M) against negligible debt, and free cash flow is positive. The discounted cash‑flow model values the firm at $5.64, implying a substantial undervaluation relative to the current price, while the forward PE (23.3×) sits just below the industry average (25.7×).
Market Outlook
Short Term
< 1 yearNeutral
Model confidence: 5/10
Key Factors
- Price at resistance with bearish trend direction
- Neutral technicals (RSI 58, modest bullish MACD)
- Low beta (0.32) limiting upside in volatile market
Medium Term
1–3 yearsPositive
Model confidence: 7/10
Key Factors
- Strong revenue growth (37%) and healthy gross margin
- Robust cash position and positive free cash flow
- DCF implied upside >150% versus current price
Long Term
> 3 yearsPositive
Model confidence: 6/10
Key Factors
- Long‑term demand for health‑information analytics services
- Potential to convert operating losses to profitability
- Undervalued relative to forward earnings and industry peers
Key Metrics & Analysis
Financial Health
Revenue Growth37.00%
Profit Margin-9.50%
P/E Ratio23.3
ROE-9.61%
ROA-5.15%
Debt/Equity0.04
P/B Ratio2.2
Op. Cash Flow$2.9M
Free Cash Flow$3.9M
Industry P/E25.7
Technical Analysis
TrendBearish
RSI58.2
Support$2.01
Resistance$2.10
MA 20$2.06
MA 50$2.08
MA 200$2.10
MACDBullish
VolumeStable
Fear & Greed Index78.8
Valuation
Fair Value$5.64
Target Price$2.10
Upside/Downside0.00%
GradeUndervalued
TypeGrowth
Risk Assessment
Beta0.32
Volatility11.12%
Sector RiskMedium
Reg. RiskMedium
Geo RiskLow
Currency RiskLow
Liquidity RiskHigh
Similar Tickers
This analysis may contain inaccuracies and is provided for informational and research purposes only. It is not personal investment advice, a recommendation, or an instruction to buy, sell, or hold any asset.